ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.89
+10.65%Year over year
Reported trailing growth
- Revenue
- +76.1%
- EBITDA
- +163.4%
- EBIT
- +139.9%
- EPS
- +129.5%
- Free cash flow
- +154.9%
- Operating cash flow
- +160.0%
Forward estimates
Based on analyst estimates
- Revenue
- +37.1%
- EBITDA
- +323.4%
- EPS
- +288.5%
Three-year CAGR
- Revenue
- +367.3%
- EBITDA
- +101.6%
- EBIT
- +90.5%
- Net income
- +88.5%
- EPS
- +88.8%
- Free cash flow
- +94.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026